5% Imiquimod cream and reflectance-mode confocal microscopy as adjunct modalities to Mohs micrographic surgery for treatment of basal cell carcinoma

Dermatologic Surgery

Volumn 30, Issue 12 I, 2004, Pages 1462-1469

  Torres, Abel ^a   Niemeyer, Agnieszka ^a   Berkes, Beatrice ^a   Marra, Diego ^e   Schanbacher, Carl ^b   González, Salvador ^c   Owens, Mary ^d   Morgan, Blaine ^d  

^a LOMA LINDA UNIVERSITY MEDICAL CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d 3M COMPANY   (United States)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

IMIQUIMOD;

ADULT; AGED; ARTHRITIS; ARTICLE; BASAL CELL CARCINOMA; BURSITIS; CHEMOSURGERY; CLINICAL TRIAL; CONFOCAL MICROSCOPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ERYTHEMA; FACE EDEMA; FEMALE; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MUSCULOSKELETAL DISEASE; NAUSEA; NEUROLOGIC DISEASE; PAIN; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SIDE EFFECT; SINUSITIS; STOMATITIS; TREATMENT INDICATION; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT DISEASE; URINARY TRACT INFECTION;

EID: 11144244267     PISSN: 10760512     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1524-4725.2004.30504.x     Document Type: Article

References (14)

1. Rowe DE, Carroll RJ, Day CL. Long-term recurrence rates in previously untreated (primary) basal cell carcinoma: implications for patient follow-up. J Dermatol Surg Oncol 1989;15:315-28.
2. Wolf DJ, Zitelli JA. Surgical margins for basal cell carcinoma. Arch Dermatol 1987;123:340-4.
3. Burg G, Hirsch RD, Konz B, Braun-Falco O. Histographic surgery: accuracy of visual assessment of the margins of basal-cell epithelioma. J Dermatol Surg 1975;1:21-4.
4. Anthony ML. Surgical treatment of nonmelanoma skin cancer. AORN J 2000;71:552-64.
5. Beutner K, Geisse JK, Helman D, et al. Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. J Am Acad Dermatol 1999;41:1002-7.
6. Shumack S, Robinson J, Kossard S, et al. Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens. Arch Dermatol 2002;138:1165-71.
7. Marks R, Gebauer K, Shumack S, et al. Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose-response trial. J Am Acad Dermatol 2001;44:807-13.
8. Geisse JK, Rich P, Pandya A. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a double-blind, randomized, vehicle-controlled study. J Am Acad Dermatol 2002;47:390-8.
9. Arany I, Tyring SK, Stanley MA, et al. Enhancement of the innate and cellular immune response in patients with genital warts treated with topical imiquimod cream 5%. Antiviral Res 1999;43:55-63.
10. Tannous Z, Torres A, Gonzalez S. In vivo real-time confocal reflectance microscopy: a noninvasive guide for Mohs micrographic surgery facilitated by aluminum chloride, an excellent contrast enhancer. Dermatol Surg 2003;29:839-46.
11. Gonzalez S, Tannous Z. Real-time, in vivo confocal reflectance microscopy of basal cell carcinoma. J Am Acad Dermatol 2002;47:869-74.
12. Rajadhyaksha M, Gonzalez S, Zavislan J, et al. In vivo confocal scanning laser microscopy of human skin, II. Advances in instrumentation and comparison with histology. J Invest Dermatol (1999);113:293-303.
13. Tamhane AC, Hochberg Y, Dunnett CW. Multiple test procedures for dose finding. Biometrics (1996);52:21-37.
14. European Committee for Proprietary Medicinal Products (CPMP). Points to Consider on Multiplicity Issues in Clinical Trials [Internet]. London: European Agency for the Evaluation of Medicinal Products, 2002 Sep 19 [accessed 23 Apr 2003]. Available from: http://www.emea.eu.int/pdfs/human/ewp/090899en.pdf